ArticlePhysics and imaging in radiation oncology2026
Optimal radiotherapy dose scheduling with variable fraction sizes and breaks via sequential mixed-integer convex programming.
Article in Physics and imaging in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Adaptive and sequential cancer therapies emerge from treatment schedule optimization.Research square · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Background and Purpose: Radiotherapy is typically delivered in consecutive equi-dose fractions, but research suggests a non-uniform dose schedule may produce a higher tumor control probability (TCP). We developed an optimization method that automatically constructs the best dose schedule with variable fraction sizes and treatment breaks based on a tumor dose-response model calibrated to head-and-neck squamous cell carcinoma, which captures the impact of cellular resource competition and hypoxia. Materials and Methods: We formulated the dose scheduling problem as a finite-horizon optimal control problem. Fraction size was constrained by an upper bound on the biologically effective dose to normal tissue, along with a daily dose limit. This problem is nonconvex, so we employed a heuristic called the convex-concave procedure to solve a sequence of mixed-integer convex approximations that converges to a good estimate of the solution. Results: The optimal schedules adhered to a pattern consisting of an initial "primer shot", followed by a 1 week break, and concluding with six small equi-dose fractions and a final large fraction. The primer shot killed proliferating cells, freeing up resources so hypoxic cells could reoxygenate during the treatment break. These reoxygenated cells are more radiosensitive, therefore the schedule waited until all cells have reoxygenated before delivering its largest dose. In computational experiments, our schedule achieved a 12% higher TCP than the standard equi-dose weekday schedule. Conclusions: An optimization method was developed to construct non-uniform dose schedules based on a model of tumor dose-response in the presence of hypoxia, yielding significant improvements in TCP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.